Topics
Diffuse midline glioma | Treatment | Targeted therapy | PARP inhibitors
Home > Publications > Topics > Diffuse midline glioma > Treatment > Targeted therapy > PARP inhibitors
Guo Y, Li Z, Parsels LA, Wang Z, Parsels JD, Dalvi A, The S, Hu N,
Valvo VM, Doherty R, Peterson E, Wang X, Venkataraman S, Agnihotri
S, Venneti S, Wahl DR, Green MD, Lawrence TS, Koschmann C, Morgan
MA, Zhang Q.
H3K27M diffuse midline
glioma is homologous recombination
defective and sensitized to radiotherapy and
NK cell-mediated antitumor immunity
by PARP inhibition.
bioRxiv
[Preprint]. 2024 Aug 27:2024.08.26.609803. doi:
10.1101/2024.08.26.609803. PMID:
39253432. Laboratory investigation. ˍ